Results 121 to 130 of about 64,440 (255)
Microchimerism in Graves’ Disease [PDF]
, 2012 Microchimerism is the presence of cells from one individual in another genetically distinct individual. Pregnancy is the main cause of natural microchimerism through transplacental bidirectional cell trafficking between mother and ...
Galofre, J.C. (Juan Carlos)
core
Advanced Science, EarlyView.This study integrates two complementary traditional Chinese medicine components as precursors to synthesize bioactive AM‐AS@CDs. Compared with single‐component CDs, these dual‐component CDs exhibit enhanced antioxidant capacity and superior renoprotective effects.
Bixiao Liu +10 more
wiley +1 more source
Graves’ ophthalmopathy – thyroid eye disease
, 2019 Graves’ disease (GD) is an autoimmune disorder that affects thyroid. It is caused by antibody, named thyroid-stimulating immunoglobulin (TIS) that acts like thyroid stimulating hormone (TSH), resulting in thyroid hormone overproduction – condition called
Nazzal, Rashed Mustafa +3 more
core
Graves' Disease Associated with Goserelin Acetate [PDF]
, 2002 We describe a case of Graves' disease associated with goserelin acetate. A 47-year-old woman experienced thyrotoxicosis during the administration of goserelin acetate, a gonadotropin-releasing hormone (GnRH) -agonist.
Ueda, Yasuo, Morita, Shigeki
core
A Plug‐and‐Play Platform for Customizing Multivalent Degraders and Degrader‐Drug Conjugates
Advanced Science, EarlyView.Membrane proteins remain challenging targets for conventional TPD approaches. Here, the authors develop UPTAB, a modular platform leveraging ultrahigh‐affinity orthogonal Im/CL protein pairs for lysosomal degradation of membrane proteins. Mono‐targeted (Type‐I), dual‐targeted (Type‐II), and tri‐targeted (Type‐III) UPTABs enable simultaneous degradation
Mengqing Zhao +7 more
wiley +1 more source
Advanced Science, EarlyView.ABSTRACT Lung adenocarcinoma (LUAD) remains a leading cause of cancer mortality with limited therapeutic options. Disulfidptosis, a novel cell death modality driven by disulfide stress, represents a promising target, yet its regulation in LUAD is poorly defined. Here, we identify Pannexin 2 (PANX2) as a tumor suppressor in LUAD.
Yi Chen +7 more
wiley +1 more source
Graves disease (clinical lecture)
Эндокринная хирургия, 2013 V E Vanushko, V V Fadeev
doaj +1 more source
Advanced Science, EarlyView.A sulfated polysaccharide (SCP) from Cyclocarya paliurus alleviates ulcerative colitis by reshaping the gut microbiome. This remodeled microbiota orchestrates the upregulation of the host‐derived lipid 12‐HEPE, which directly inhibits the TLR4/NF‐κB pathway to suppress inflammation.
Xianxiang Chen +11 more
wiley +1 more source
Diagnostic Approaches to and Disaese Course Modifying Therapies in Graves Orbitopathy
Graves' Orbitopathy (GO) is an autoimmune condition that primarily affects the orbit, causing inflammation, muscle expansion, and tissue changes. Although often linked to Graves' Disease (GD), 5-10% of GO patients may not have GD at diagnosis.
Muthomi, Brenda Shey Wanjira
core
Advanced Science, EarlyView.We present the MyoRobot 3.0, an advanced platform that combines high‐resolution imaging with automated mechanical testing to improve the accuracy of single muscle fibre analysis. The system tracks fibre diameter changes during stretch, preventing major stress miscalculations.
Michael Haug +5 more
wiley +1 more source